Possible protective role of chloramphenicol in TSST-1 and coagulase-positive Staphylococcus aureus-induced septic arthritis with altered levels of inflammatory mediators.

Inflammation
Sayantani MajumdarBiswadev Bishayi

Abstract

Chloramphenicol is mostly used against coagulase-negative Staphylococcus aureus, and its protective role against coagulase-positive S. aureus is not well studied. In our study, arthritis was induced in mice by S. aureus (Apollo Gleneagles 33 (AG-33) or American Type Culture Collection 25923 (ATCC-25923)) infection. Chloramphenicol was administered after 2 h of infection. Mice were killed at 1, 3, 5 days post-infection. Mice inoculated with pathogenic Staphylococci (AG-33) expressing coagulase and Toxic shock syndrome toxin-1 (TSST-1), displayed severe arthritis with enhanced bacterial burden in the spleen, cytokine production in serum and synovial tissue, neutrophil recruitment, and cyclooxegenase-2 expression in synovial tissue compared with ATCC-25923-infected groups. Severity of arthritis was regulated by chloramphenicol treatment. Our study suggests that alteration in the inflammatory cytokine levels and pronounced production of cyclooxygenase-2 play important roles in progression of arthritis which is regulated by application of chloramphenicol.

References

Aug 1, 1991·Infection and Immunity·T BremellA Tarkowski
Nov 1, 1990·Arthritis and Rheumatism·T BremellA Tarkowski
Mar 1, 1989·Reviews of Infectious Diseases·P J van den Broek
Feb 1, 1988·Antimicrobial Agents and Chemotherapy·J B McClainR Rice
Mar 21, 1985·The New England Journal of Medicine·D L Goldenberg, J I Reed
Jul 1, 1994·Clinical and Experimental Immunology·F M Brennan
Aug 1, 1995·The Journal of Antimicrobial Chemotherapy·C G Gemmell
Mar 1, 1996·Journal of Medical Microbiology·R CunninghamH Humphreys
Feb 5, 1998·Lancet·D L Goldenberg
May 5, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·D L LefkowitzN Moguilevsky
Aug 30, 2000·Nature·M L Cohen
Feb 15, 2001·Arthritis Research·O H HultgrenA Tarkowski
Jul 4, 2001·Trends in Microbiology·A TarkowskiM Verdrengh
Oct 5, 2002·Clinical Microbiology Reviews·Mark E Shirtliff, Jon T Mader
Nov 28, 2002·Clinical and Experimental Immunology·I GjertssonA Tarkowski
Dec 14, 2002·FEMS Microbiology Letters·Andrej TarkowskiMargareta Verdrengh
Jul 16, 2005·Clinical Microbiology Reviews·Bénédicte Fournier, Dana J Philpott
Oct 6, 2005·Annals of Internal Medicine·Hyon K ChoiUNKNOWN American Physiological Society
Nov 28, 2006·Best Practice & Research. Clinical Rheumatology·Andrej Tarkowski
May 23, 2007·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Raheem B Kherani, Kam Shojania
Nov 17, 2007·Cell Host & Microbe·Victor J TorresEric P Skaar
Jul 9, 2008·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·D DasB Bishayi
Feb 12, 2009·Trends in Microbiology·Christian Garzoni, William L Kelley

❮ Previous
Next ❯

Citations

Sep 3, 2013·ISRN Rheumatology·Bruna Formentão AraujoGladson Ricardo Flor Bertolini
Dec 12, 2012·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Pinky MalBiswadev Bishayi
Nov 13, 2012·Brain, Behavior, and Immunity·Sayantika MahantiBiswadev Bishayi
Dec 31, 2020·Dermatology : International Journal for Clinical and Investigative Dermatology·Iris Amitay-LaishSalomon M Stemmer

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.